AAAndrea Attanasio

Andrea Attanasio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Attanasio has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impaired Flow and Physiology in Coronaries With Anomalous Origin From the Opposite Sinus of Valsalva

    by Mauro Lo Rito, Mattia Squillace, Mauro Luca Agnifili, Antonio Rosato, Serena Anglese, Adele Chiavetta, Camilla Muritti, Miriam Deamici, Jessica Negri, Andrea Attanasio, et al.

    Background: Anomalous Aortic Origin of a Coronary Artery (AAOCA) high‐risk anatomical features (intramural segment, acute take‐off angle, slit‐like ostium) cause coronary stenosis leading to myocardial infarction. How these features alter coronary physiology remains unclear. Aims: We aimed to evaluate their impact on coronary blood supply using continuous thermodilution. Methods: We prospectively enrolled 51 AAOCA patients undergoing continuous thermodilution. Subjects were classified into an ischemic risk (IR) group (intramural segment, acute angle, oval or slit ostium) or non‐ischemic risk (no‐IR) group. Non‐anomalous coronary arteries served as controls. We measured absolute coronary blood flow (CBF) and microvascular resistance. Results: Subjects (median age 48.4 years) presented mostly with angina, syncope, and arrhythmia. Final analysis included 48 AAOCA cases (31 IR, 17 no‐IR) and 45 controls. The IR group had a median IM length of 9 mm, take‐off angle of 31.9°, and a slit‐like or oval ostium. The no‐IR group had a median angle of 51.5° and an oval or round ostium. At rest, absolute CBF and microvascular resistance showed no significant differences among groups. However, during hyperemia, the IR group had significantly reduced CBF compared to controls (179 vs. 290 mL/min, p = 0.015). The IR group demonstrated higher microvascular resistance at rest (1473 vs. 1150, p = 0.024) and during hyperemia (433 vs. 305, p = 0.012), indicating persistently increased coronary vascular tone. Conclusions: High‐risk anatomical features of AAOCA are associated with altered coronary physiology. An intramural segment, acute take‐off angle, and slit‐like or oval ostium are linked to reduced hyperemic coronary blood flow due to increased microvascular resistance.

  • Atypical Left Ventricular Remodeling in Fabry Cardiomyopathy: The Key Diagnostic Role of T1 Mapping

    by Stefano Censi, Giada De Angeli, Federico Pieruzzi, Lara Tondi, Gianluigi Guida, Giandomenico Disabato, Andrea Attanasio, Pietro Spagnolo, Gianpaolo Carrafiello, Massimo Lombardi, et al.

  • Open Access

    Predictors of Early Death in Patients With Wild‐Type Transthyretin Cardiac Amyloidosis

    by Paolo Milani, Giuseppe Damiano Sanna, Roberta Mussinelli, Marco Basset, Gianluigi Guida, Andrea Attanasio, Martina Nanci, Francesca Fabris, Claudia Bellofiore, Alessandro Fogliani, et al.

    Background: For the time being, tafamidis is the only approved treatment for wild‐type transthyretin cardiac amyloidosis. However, benefits on all‐cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age. We searched baseline variables able to discriminate patients at risk of death within 18 months. Methods and Results: We randomly divided our prospectively maintained database in 2 cohorts, a testing (two thirds) and a validating (one third) set, respectively. We used the Eastern Cooperative Oncology Group–Performance Status as a simple scoring of frailty. We analyzed the clinical, laboratory and instrumental features of 691 consecutive wild‐type transthyretin cardiac amyloidosis patients diagnosed between 2006 and 2021. Median follow‐up was 43 months, and 367 patients (53%) died. Eighteen‐month death was predicted by NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide; cutoff 4200 ng/L), cardiac troponin I (cutoff 92 ng/L), and age (cutoff 80 years). At multivariable analysis, Eastern Cooperative Oncology Group–Performance Status >1 along with the selected variables were independent prognostic determinants and outperformed New York Heart Association functional class. The combination of these variables identified standard‐ and high‐risk patients (all variables above the cutoffs) with a median survival of 57 and 17 months, respectively ( P <0.001). This was confirmed in the validation set. Conclusions: A simple scoring system including age, cardiac biomarkers, and Eastern Cooperative Oncology Group–Performance Status identifies subjects with cardiac wild‐type transthyretin cardiac amyloidosis at high risk of early death.


  • Predictors of early mortality in patients with wild-type transthyretin cardiac amyloidosis PC73 (#450)

    by Paolo Milani, Giuseppe Damiano, Roberta Mussinelli, Marco Basset, Pietro Benvenuti, Gianluigi Guida, Andrea Attanasio, Martina Nanci, Francesca Benigna, Laura Obici, et al.

    **Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER

  • Left atrial dysfunction predicts left ventricular remodelling in patients with preserved ejection fraction after acute ST-elevation myocardial infarction

    by Andrea Attanasio, Lara Tondi, Serenella Castelvecchio, Vittorio Pazzanese, Anna Palmisano, Antonio Esposito, Pietro Ameri, Claudia Canale, Alberto Cappelletti, Luca P Alberti, et al.

    Andrea Attanasio, Lara Tondi, Serenella Castelvecchio, Vittorio Pazzanese, Anna Palmisano, Antonio Esposito, Pietro Ameri, Claudia Canale, Alberto Cappelletti,


  • Open Access

    Lifestyle intervention on left atrium size and function in patients with metabolic syndrome

    by Andrea Attanasio, Gianluigi Guida, Giandomenico Disabato, Massimo F Piepoli

    Andrea Attanasio, MD, Gianluigi Guida, MD, Giandomenico Disabato, MD, Massimo F Piepoli, MD, PhD, FESC, FHFA; Lifestyle intervention on left atrium size and fun